• Member Statistics

    • 730,926 Colleagues-to-Date [Sponsored by a generous R&D grant from iMBA, Inc.]
  • Our ME-P Channels

  • ME-P Archives Silo [2006 – 2018]

  • Dr. David Marcinko [Publisher-in-Chief]

    As a Distinguished University Professor and Endowed Department Chairman, Dr. David Edward Marcinko MBBS DPM MBA MEd BSc CMP® was a NYSE broker and investment banker for a decade who was respected for his unique perspectives, balanced contrarian thinking and measured judgment to influence key decision makers in strategic education, health economics, finance, investing and public policy management.

    Dr. Marcinko is originally from Loyola University MD, Temple University in Philadelphia and the Milton S. Hershey Medical Center in PA; Oglethorpe University and Atlanta Hospital & Medical Center in GA; and Aachen City University Hospital, Koln-Germany. He is one of the most innovative global thought leaders in health care entrepreneurship today by leveraging and adding value with strategies to grow revenues and EBITDA while reducing nonessential expenditures and improving operational efficiencies.

    Professor Marcinko was a board certified physician, surgical fellow, hospital medical staff Vice President, public and population health advocate, and Chief Executive & Education Officer with more than 425 published papers; 5,150 op-ed pieces and over 135+ domestic / international presentations to his credit; including the top ten [10] biggest drug and pharmaceutical companies and financial services firms in the nation. He is also a best-selling Amazon author with 30 published text books in four languages [National Institute of Health, Library of Congress and Library of Medicine].

    Dr. Marcinko is past Editor-in-Chief of the prestigious “Journal of Health Care Finance”, and a former Certified Financial Planner® who was named “Health Economist of the Year” in 2010, by PM magazine. He is a Federal and State court approved expert witness featured in hundreds of peer reviewed medical, business, economics and trade publications [AMA, ADA, APMA, AAOS, Physicians Practice, Investment Advisor, Physician’s Money Digest and MD News] etc.

    Dr. Marcinko is also an early-stage investor with a focus on finance, economics and business IT. He was on the initial team for Physicians-Nexus®, 1st. Global Financial Advisors and Physician Services Group Inc; and as a mentor for Deloitte-Touche, Accenture and other start-ups in Silicon Valley, CA.

    As a licensed life and health insurance agent, RIA – SEC registered representative, Dr. Marcinko was Founding Dean of the fiduciary niche focused CERTIFIED MEDICAL PLANNER® online chartered designation education program; as well as Chief Editor of the HEALTH DICTIONARY SERIES® Wiki Project.

    Dr. Marcinko’s professional memberships included: ASHE, AHIMA, ACHE, ACME, ACPE, MGMA, FMMA and HIMSS. He was a MSFT Beta tester, Google Scholar, “H” Index favorite and one of LinkedIn’s “Top Cited Voices”. Marcinko is “ex-officio” and R&D Scholar-on-Sabbatical for iMBA, Inc. who was recently appointed to the MedBlob® [military encrypted medical data warehouse and health information exchange] Advisory Board.



  • Hope Hetico RN MS [Managing Editor]

    Prof. Hetico





    USNews.com, Reuters.com,
    News Alloy.com,
    and Congress.org

    Comprehensive Financial Planning Strategies for Doctors and Advisors: Best Practices from Leading Consultants and Certified Medical Planners(TM)

    Product Details

    Product Details

    Product Details


    New "Self-Directed" Study Option SinceJanuary 1st, 2018
  • PodiatryPrep.org

    Lower Extremity Trauma
    [Click on Image to Enlarge]

  • Most Recent ME-Ps

  • ME-P Free Adverting Sales Consultation

    The “Medical Executive-Post” is about connecting doctors, health care executives and modern consulting advisors. It’s about free-enterprise, business, practice, policy, personal financial planning and wealth building capitalism. We have an attitude that’s independent, outspoken, intelligent and so Next-Gen; often edgy, usually controversial. And, our consultants “got fly”, just like U. Read it! Write it! Post it! “Medical Executive-Post”. Call or email us for your FREE advertising and sales consultation TODAY [770.448.0769]

    Product Details

    Product Details

  • Medical & Surgical e-Consent Forms

  • iMBA White Papers

    Customized Industry Topics [$1,500 unlimited corporate license]January 1st, 2018
    Medical Clinic Valuations * Endowment Fund Management * Health Capital Formation * Investment Policy Statement Analysis * Provider Contracting & Negotiations * Marketplace Competition * Revenue Cycle Enhancements; and more! HEALTHCARE FINANCIAL INDUSTRIAL COMPLEX
  • Ann Miller RN MHA [Executive-Director]

    iMBA VIRTUAL OFFICES [1.770.448.0769] Atlanta, GA.
    Location doesn't matter. We welcome new long-distance clients and colleagues.

  • ME-P Publishing


    If you want the opportunity to work with leading health care industry insiders, innovators and watchers, the “ME-P” may be right for you? We are unbiased and operate at the nexus of theoretical and applied R&D. Collaborate with us and you’ll put your brand in front of a smart & tightly focused demographic; one at the forefront of our emerging healthcare free marketplace of informed and professional “movers and shakers.” Our Ad Rate Card is available upon request [770-448-0769].

  • Reader Comments, Quips, Opinions, News & Updates

  • Start-Up Advice for Businesses, DRs and Entrepreneurs

    ImageProxy “Providing Management, Financial and Business Solutions for Modernity”
  • Up-Trending ME-Ps

  • Capitalism and Free Enterprise Advocacy

    Whether you’re a mature CXO, physician or start-up entrepreneur in need of management, financial, HR or business planning information on free markets and competition, the "Medical Executive-Post” is the online place to meet for Capitalism 2.0 collaboration. Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds. ******************************************************************** THE ME-P DISCLAIMER: Posts, comments and all opinions do not necessarily represent iMBA, Inc. Copyright © 2006 to-date.
  • OIG Fraud Warnings

    Beware of health insurance marketplace scams OIG's Most Wanted Fugitives at oig.hhs.gov
  • Advertisements

Federal Drug Detailing Program

New Proposal for “Academic” Detailing

[By Staff Writers]

Join Our Mailing List 

A bill will soon be introduced in the United States Senate that would offer physicians an alternative source for the latest information about new drugs, instead of relying on pharmaceutical manufacturers and retail drug representatives.  

The Proposal 

The legislation, sponsored by Senators Herb Kohl (D-Wisconsin) and Dick Durbin (D-Ill.) would create a federal “academic” detailing program to produce independent educational materials for physicians and medical professionals on the safety and comparative effectiveness of prescription drugs.

This would include generic and over-the-counter products, based on research at pharmacy and medical schools, according to Modern Physician.  


Now, some academic detailing services have already been implemented at the state level and by integrated health systems such as Kaiser Permanente, while preliminary results suggest that these programs have effectively changed prescribing behavior while reducing health care costs. 


And so, what are your thoughts on the matter; please comment and opine? 


Product DetailsProduct DetailsProduct Details



2 Responses

  1. Dear Ann and All ME-P Readers,

    The Observational Medical Outcomes Partnership: Improving Post-Market Drug Safety

    Research Project Aims To Improve Accuracy and Timeliness of Detecting Drug Risks and Benefits in Post-Market Environment

    Bethesda, MD (December 6, 2010) – The Foundation for the National Institutes of Health (FNIH) announced the release of the publication “Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership” in the Annals of Internal Medicine: Ann Intern Med November 2, 2010 153:600-606.

    The Observational Medical Outcomes Partnership (OMOP) is a public-private partnership composed of representatives from the FDA, academia, 17 corporate and nonprofit organizations in the pharmaceutical industry and health care providers with large health claim or electronic health record databases. The partnership is focused on the need to advance the science of active medical product safety surveillance by using existing health databases.

    OMOP’s transparent, open innovation approach is designed to provide evidence that can inform a viable national program of active drug safety surveillance. OMOP’s research program consists of systematic and empiric investigations of numerous methods and types of observational databases that could become the infrastructure of active surveillance. This article describes the governance structure, data-access model, methods-testing approach, and technology development. The program of study is well under way.

    “FDA is very enthusiastic about the Observational Medical Outcomes Partnership,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research and chairwoman of the partnership’s executive board. “The partnership presents a substantial opportunity to help develop the tools and expertise needed to improve medical product safety and have a positive impact on health.”

    In addition to sponsoring specific research efforts, OMOP has created tools that have been placed in the public domain to enable parallel research into drug safety by a broader community of scientific investigators. This includes: experimental protocols, a common data model, database evaluation software, and analytical methods software. Based on the public health mission of the Partnership, all findings from the research project will be made public, including comprehensive reports on the scientific and technical findings, lessons learned, peer-reviewed articles on specific experimental findings by sponsored investigators.

    The Observational Medical Outcomes Partnership is funded through, and managed by the Foundation for the National Institutes of Health. “As drug safety concerns increase and budgets tighten, it’s more important than ever that the public and private sectors work together to identify drug safety issues in the market environment and mitigate public health risks,” concludes Janet Woodcock.

    About the Foundation for NIH

    Established by the United States Congress to support the mission of the NIH-improving health through scientific discovery in the search for cures-the Foundation for NIH is a leader in identifying and addressing complex scientific and health issues. The foundation is a non-profit, 501(c)(3) charitable organization that raises private-sector funds for a broad portfolio of unique programs that complement and enhance NIH priorities and activities. For additional information about the Foundation for NIH, please visit http://www.fnih.org.

    Press Contact:
    Richard Scarfo


  2. Teva divests $1 billion in assets in Allergan deal

    The Israeli pharmaceutical company will shed the assets to deal with antitrust issues in its proposed takeover of Allergan’s generic drug business.


    The purchase is scheduled to be completed in the first quarter of 2016, opening the way for Allergan’s subsequent merger with Pfizer.



Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: